Nephros (NEPH) Competitors $4.33 +0.15 (+3.59%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NEPH vs. STIM, KRMD, SGHT, CVRX, RCEL, NYXH, MBOT, LNSR, LAKE, and SPAIShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include Neuronetics (STIM), KORU Medical Systems (KRMD), Sight Sciences (SGHT), CVRx (CVRX), Avita Medical (RCEL), Nyxoah (NYXH), Microbot Medical (MBOT), LENSAR (LNSR), Lakeland Industries (LAKE), and Safe Pro Group (SPAI). These companies are all part of the "medical equipment" industry. Nephros vs. Its Competitors Neuronetics KORU Medical Systems Sight Sciences CVRx Avita Medical Nyxoah Microbot Medical LENSAR Lakeland Industries Safe Pro Group Nephros (NASDAQ:NEPH) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Do institutionals and insiders have more ownership in NEPH or STIM? 41.1% of Nephros shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 6.7% of Nephros shares are owned by insiders. Comparatively, 8.7% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is NEPH or STIM more profitable? Nephros has a net margin of 7.95% compared to Neuronetics' net margin of -43.47%. Nephros' return on equity of 14.89% beat Neuronetics' return on equity.Company Net Margins Return on Equity Return on Assets Nephros7.95% 14.89% 11.64% Neuronetics -43.47%-156.36%-35.69% Which has preferable valuation and earnings, NEPH or STIM? Nephros has higher earnings, but lower revenue than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNephros$14.16M3.24$70K$0.1236.08Neuronetics$74.89M2.36-$43.71M-$1.13-2.37 Do analysts prefer NEPH or STIM? Nephros presently has a consensus target price of $5.50, indicating a potential upside of 27.02%. Neuronetics has a consensus target price of $7.00, indicating a potential upside of 161.68%. Given Neuronetics' higher possible upside, analysts plainly believe Neuronetics is more favorable than Nephros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Neuronetics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, NEPH or STIM? Nephros has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Does the media prefer NEPH or STIM? In the previous week, Neuronetics had 2 more articles in the media than Nephros. MarketBeat recorded 3 mentions for Neuronetics and 1 mentions for Nephros. Nephros' average media sentiment score of 1.89 beat Neuronetics' score of 0.48 indicating that Nephros is being referred to more favorably in the media. Company Overall Sentiment Nephros Very Positive Neuronetics Neutral SummaryNephros beats Neuronetics on 9 of the 15 factors compared between the two stocks. Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.74M$10.51B$5.65B$10.31BDividend YieldN/A1.92%5.75%4.64%P/E Ratio35.9620.4676.2125.99Price / Sales3.2428.57560.97124.87Price / Cash207.3924.1037.5461.24Price / Book5.353.3312.486.28Net Income$70K$212.47M$3.29B$270.94M7 Day Performance3.59%-2.60%0.54%-0.21%1 Month Performance7.18%-5.58%3.06%5.68%1 Year Performance141.90%-12.23%61.86%27.59% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros3.5385 of 5 stars$4.33+3.6%$5.50+27.0%+133.5%$45.74M$14.16M35.9630Positive NewsSTIMNeuronetics1.6584 of 5 stars$2.82-1.9%$7.00+148.7%+238.8%$186.14M$111.11M-2.49180KRMDKORU Medical Systems2.3728 of 5 stars$4.01+1.8%$4.63+15.3%+45.2%$185.40M$36.85M-44.5680Positive NewsSGHTSight Sciences3.5346 of 5 stars$3.46-1.7%$4.42+27.6%-46.7%$181.20M$79.87M-3.60210Gap UpCVRXCVRx2.7418 of 5 stars$6.77-2.2%$14.00+106.9%-18.0%$176.80M$51.29M-3.22160RCELAvita Medical2.3849 of 5 stars$6.25-7.5%$11.60+85.6%-48.8%$166.37M$74.88M-3.17130NYXHNyxoah2.5309 of 5 stars$4.63-2.9%$15.00+224.0%-47.6%$157.70M$4.89M-2.01110MBOTMicrobot Medical2.2453 of 5 stars$3.44+0.4%$12.00+249.3%+282.6%$156.92MN/A-5.9420Gap UpLNSRLENSAR1.5412 of 5 stars$12.41+0.6%$15.00+20.9%+172.2%$148.11M$58.36M-2.95110News CoveragePositive NewsLAKELakeland Industries4.8747 of 5 stars$14.61+0.8%$25.00+71.2%-26.9%$139.77M$167.21M-5.332,100SPAISafe Pro Group3.3049 of 5 stars$7.35-0.8%$10.50+42.9%+145.8%$138.25M$2.17M-9.1911Positive News Related Companies and Tools Related Companies Neuronetics Competitors KORU Medical Systems Competitors Sight Sciences Competitors CVRx Competitors Avita Medical Competitors Nyxoah Competitors Microbot Medical Competitors LENSAR Competitors Lakeland Industries Competitors Safe Pro Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEPH) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NEPH Stock Alerts